A Phase Ⅱ Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment

Guangdong Association of Clinical Trials1 site in 1 country54 target enrollmentJune 2014

ConditionsSmall Cell Lung Cancer

Interventionsirinotecan

Drugsirinotecan

Overview

Phase: Phase 2
Intervention: irinotecan
Conditions: Small Cell Lung Cancer
Sponsor: Guangdong Association of Clinical Trials
Enrollment: 54
Locations: 1
Primary Endpoint: Limiting Toxicity (DLT )in the irinotecan
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to identify the appropriate dose of irinotecan by dose escalation(dose climbing) test. The study would provide rationale for regimen decision in a future phase III clinical trial, in which irinotecan combined with cisplatin(IP) will be selected as therapeutic drugs.

Detailed Description

To determine the Maximum Tolerated Dose (MTD) and Limiting Toxicity (DLTs) of irinotecan in patients with extensive stage small cell lung cancer treated with irinotecan plus cisplatin

Registry

clinicaltrials.gov

Start Date

June 2014

End Date

June 2021

Last Updated

5 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Guangdong Association of Clinical Trials

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age 18 to 65 years, male and female
•Histologically or cytologically confirmed extensive stage .small cell lung cancer(SCLC )（except metastases only as pleural effusion）
•No prior chemotherapy
•Metastatic lesion had been treated more than 14 days by palliative radiation therapy or surgery
•With measurable tumor lesions (Non-irradiated parts),(RECIST 1.1: Without radiotherapy ,the longest diameter is more than 10mm by CT or MRI ,except that lymph nodes need short diameter need more then 15mm, and the lesions can be accurately evaluated repeatedly measurable)
•Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1
•Expected survival ≥ 3months
•Marrow,kidney, liver,heart and lung are well -functioning,and absolute count of
•absolute neutrophil coun(ANC) ≥ 2.0 × 109 / L
•blood platelet(PLT) ≥ 100 × 109 / L

Exclusion Criteria

•Patient have platinum compounds allergy history
•Patient with active ulcer disease or chronic enteritis patients
•Primary lesion(s) has (have) been treated by Surgery or radiation
•Patient had received Immune drugs treatment for anti-lung cancer indications or anti-cancer Chinese traditional medicine treatment within two weeks
•Patients with interstitial pneumonia or pulmonary fibrosis
•Brain metastasis requiring treatment
•Patient with bronchus or bronchial stenosis or blockage and superior vena cava syndrome caused by serious invasion
•Patients with severe infections, severe abnormal secretion of (Anti Diuretic Hormone,ADH) syndrome, poorly controlled diabetes, severe complications requiring treatment vena cava syndrome
•Severe cardiovascular disease: hypertension that medical treatment can not be controlled , unstable angina, myocardial infarction within the last June a history of congestive heart failure\> 3 (NYHA) and severe arrhythmia